Abstract
Background
Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited.
Objective
The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose intensity, and risk of developing PSE were investigated by studying Taiwanese health claims (2003–2013).
Methods
Patients with new-onset ischaemic stroke were identified. The main outcome was a diagnosis of epilepsy after ischaemic stroke. According to pre-stroke statin use, groups of current users, former users, and non-users were compared using ANOVA. An extended Cox regression model was utilized to estimate the hazard ratio (HR) of PSE, with post-stroke statin use and certain comedications as time-dependent variables. Serial sensitivity analyses were performed to ensure study robustness.
Results
Of the 20,858 ischaemic stroke patients, 954 (4.6%) developed PSE. Post-stroke statin use (adjusted HR (aHR) 0.55; 95% confidence interval 0.46–0.67, p < 0.001), but not pre-stroke statin use was associated with a significantly reduced risk of developing PSE. A dose-response correlation was also observed between PSE risk reduction and quartiles of the statin cumulative defined daily dose (cDDD) (aHR 0.84, 0.67, 0.53, and 0.50 for the lowest, second, third, and highest quartiles of cDDD, respectively). Risk predictors and protectors against PSE were also characterized.
Conclusion
The post-stroke use of statins after ischaemic stroke was associated with PSE risk reduction in a cDDD-dependent manner. Further clinical studies on the potential applications of statins for PSE prophylaxis, particularly among at-risk patients, are warranted.
Similar content being viewed by others
References
Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol. 2002;59:195–201.
Jungehulsing GJ, Heuschmann PU, Holtkamp M, Schwab S, Kolominsky-Rabas PL. Incidence and predictors of post-stroke epilepsy. Acta Neurol Scand. 2013;127:427–30.
Chen TC, Chen YY, Cheng PY, Lai CH. The incidence rate of post-stroke epilepsy: a 5-year follow-up study in Taiwan. Epilepsy Res. 2012;102:188–94.
Guo J, Guo J, Li J, et al. Statin treatment reduces the risk of poststroke seizures. Neurology. 2015;85:701–7.
Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke. 2004;35:1769–75.
Lamy C, Domigo V, Semah F, et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology. 2003;60:400–4.
Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S1–45.
McFarland AJ, Anoopkumar-Dukie S, Arora DS, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15:20607–37.
Vaughan CJ, Delanty N, Basson CT. Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? CNS Drugs. 2001;15:589–96.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117–25.
Zacco A, Togo J, Spence K, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11.
Seker FB, Kilic U, Caglayan B, et al. HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Neuroscience. 2015;284:349–59.
Etminan M, Samii A, Brophy JM. Statin use and risk of epilepsy: a nested case–control study. Neurology. 2010;75:1496–500.
Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. J Formos Med Assoc. 2015;114:254–9.
Jette N, Beghi E, Hesdorffer D, et al. ICD coding for epilepsy: past, present, and future—a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy. Epilepsia. 2015;56:348–55.
Chang CH, Lin CH, Caffrey JL, et al. Risk of intracranial hemorrhage from statin use in Asians: a nationwide cohort study. Circulation. 2015;131:2070–8.
Sung SF, Hsieh CY, Yang YHK, et al. Developing a stroke severity index based on administrative data was feasible using data mining techniques. J Clin Epidemiol. 2015;68:1292–300.
Sung SF, Hsieh CY, Lin HJ, et al. Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res. 2016;16:509.
Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269–75.
De Simoni MG, Perego C, Ravizza T, et al. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci. 2000;12:2623–33.
Gouveia TL, Scorza FA, Iha HA, et al. Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav. 2014;36:68–73.
Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2442–9.
Lossius MI, Ronning OM, Slapo GD, Mowinckel P, Gjerstad L. Poststroke epilepsy: occurrence and predictors—a long-term prospective controlled study (Akershus Stroke Study). Epilepsia. 2005;46:1246–51.
Zhao RR, Xu XC, Xu F, et al. Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. Biochem Biophys Res Commun. 2014;448:414–7.
Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc. 2009;57:237–42.
Graham NS, Crichton S, Koutroumanidis M, Wolfe CD, Rudd AG. Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register. Stroke. 2013;44:605–11.
Huang CW, Saposnik G, Fang J, Steven DA, Burneo JG. Influence of seizures on stroke outcomes: a large multicenter study. Neurology. 2014;82:768–76.
Al-Khaled M, Matthis C, Eggers J. Statin treatment in patients with acute ischemic stroke. Int J Stroke. 2014;9:597–601.
Xu T, Yu X, Ou S, Liu X, Yuan J, Chen Y. Statin adherence and the risk of stroke: a dose-response meta-analysis. CNS Drugs. 2017;31:263–71.
Curtis M, Deng Y, Lee VV, et al. Effect of dose and timing of preoperative statins on mortality after coronary artery bypass surgery. Ann Thorac Surg. 2017;104:782–9.
Ferlazzo E, Gasparini S, Beghi E, et al. On behalf of Epilepsy Study Group of the Italian Neurological Society. Epilepsy in cerebrovascular diseases: review of experimental and clinical data with meta-analysis of risk factors. Epilepsia. 2016;57:1205–14.
Xie C, Sun J, Qiao W, et al. Administration of simvastatin after kainic acid-induced status epilepticus restrains chronic temporal lobe epilepsy. PLoS One. 2011;6:e24966.
Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol. 2012;65:1171–80.
Cheng C-L, Kao YHY, Lin S-J, Lee C-H, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:236–42.
Sung S-F, Hsieh C-Y, Lin H-J, Chen Y-W, Kao YHY, Li C-Y. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. Int J Cardiol. 2016;215:277–82.
Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was based on healthcare data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare, and previously managed by the National Health Research Institutes. The data founders and providers had no role in the study design, data analysis, data interpretation, or writing of the report.
Conflict of interest
Fang-Ju Lin, Hung-Wei Lin, and Yunn-Fang Ho declare no conflicts of interest.
Funding
No funding was received for the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lin, FJ., Lin, HW. & Ho, YF. Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims. CNS Drugs 32, 367–376 (2018). https://doi.org/10.1007/s40263-018-0501-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-018-0501-0